Background: The necessity for extended drug discharge to alleviate pain without adverse effects underscores the importance of innovative drug delivery systems. Achieving sustained pain relief without compromising patient safety is a critical objective in healthcare. By extending the duration of drug action while suppressing side effects, such systems offer enhanced therapeutic outcomes and improved patient quality of life.
Objective: This study endeavors to develop and appraise an innovative implantable drug delivery system by integrating NSAID-loaded gelatin microcapsules into a gelatin scaffold designed to augment drug delivery efficiency and sustain drug release.
Method: Piroxicam-loaded microcapsules with a 1:1 ratio of poly lactic acid and poly lacto glycolic acid showed smaller particle size, good yield, entrapment efficiency, and discharge. They were selected to make gelatin scaffolds with Box Behnken Design using Design Expert software for optimization. The better scaffolds were made in the form of rod-shaped sub-dermal implants. The primary focus of the investigation was the evaluation of critical parameters, specifically entrapment efficiency and drug discharge properties as dependent variables.
Results: Microcapsules with a 1:1 ratio of PLA and PLGA showed smaller particle sizes, good yield, entrapment efficiency, and discharge. Notably, the Design Expert-driven optimization yields highly favorable results. Furthermore, the scaffolds loaded with microcapsules exhibited favorable physicochemical assets, including drug discharge, for an extended period, underscoring their versatility for drug delivery.
Conclusion: By employing Design Expert software for optimization, the study demonstrates promising results, particularly in sustained pain management for arthritis, potentially improving therapeutic outcomes and patient quality of life. The study concludes that the prepared implants (holding scaffolds impregnated with piroxicam-loaded microcapsules) can be promising for relieving arthritis all day.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0122117385332757241104104727 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pharmacokinetic/Pharmacodynamic Study of Esomeprazole Comparing a Dual Delayed-Release Formulation (YYD601) to a Conventional Formulation Following Multiple Administrations in Healthy Adult Subjects.
Drug Des Devel Ther
January 2025
School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, Daegu, 41944, Republic of Korea.
Background: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.
Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.
Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days.
Cardiac-targeted delivery of a novel Drp1 inhibitor for acute cardioprotection.
J Mol Cell Cardiol Plus
September 2024
O'Brien Institute Department, St Vincent's Institute of Medical Research, Victoria 3065, Australia.
Dynamin-related protein 1 (Drp1) is a mitochondrial fission protein and a viable target for cardioprotection against myocardial ischaemia-reperfusion injury. Here, we reported a novel Drp1 inhibitor (DRP1i1), delivered using a cardiac-targeted nanoparticle drug delivery system, as a more effective approach for achieving acute cardioprotection. DRP1i1 was encapsulated in cubosome nanoparticles with conjugated cardiac-homing peptides (NanoDRP1i1) and the encapsulation efficiency was 99.
View Article and Find Full Text PDFOvercoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.
Cancer Drug Resist
December 2024
Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences; Tianjin Medical University, Tianjin 300070, China.
Drug resistance is a major challenge in cancer therapy that often leads to treatment failure and disease relapse. Despite advancements in chemotherapeutic agents and targeted therapies, cancers often develop drug resistance, making these treatments ineffective. Extracellular vesicles (EVs) have gained attention for their potential applications in drug delivery because of their natural origin, biocompatibility, and ability to cross biological barriers.
View Article and Find Full Text PDFHyaluronic acid/silk fibroin nanoparticles loaded with methotrexate for topical treatment of psoriasis.
Int J Pharm X
June 2025
State Key Laboratory of Resource Insects, Key Laboratory for Sericulture Biology and Genetic Breeding, Ministry of Agriculture and Rural Affairs, College of Sericulture, Textile and Biomass Sciences, Yibin Academy, Southwest University, Chongqing 400715, China.
Systemic administration of methotrexate (MTX), widely regarded as one of the most effective treatments for psoriasis, poses significant challenges due to its high toxicity, limited solubility, and potential for adverse effects. Consequently, developing a topical form of MTX may offer a safer and more effective strategy for psoriasis management. Silk fibroin (SF), a protein-based biomacromolecule, has shown considerable promise as a nanocarrier for sustained and targeted drug delivery, owing to its exceptional physicochemical and biological properties.
View Article and Find Full Text PDFData characterizing a panel of biodegradable cross-linked polyester implants for sustained delivery of an anti-viral drug.
Data Brief
February 2025
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.
Tenofovir alafenamide (TAF) is currently administered orally to patients for treatment of chronic hepatitis B virus infection and as a part of a combination therapy for human immunodeficiency virus (HIV) infection. A long-acting delivery system could provide several advantages as a formulation strategy for this drug including improved patient adherence, convenience, more consistent drug levels and potentially fewer side effects. To date, the vast majority of polymer-based long-acting delivery systems have been prepared from poly(lactide--glycolide) [1].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!